Seeking Alpha

Poonam A. Arora

 
View Poonam A. Arora's StockTalks BY TICKER:
  • Poonam A. Arora
    Puma Biotechnology: Shares Overbought At Current Levels $PBYI http://seekingalpha.com/a/1e8s9
    Jul 26, 3:55 PM
    Reply
      • Poonam A. Arora
        Epizyme: Undervalued Rare Asset With Outsized Potential $EPZM http://seekingalpha.com/a/1csnt
        Jun 20, 7:30 AM
        Reply
          • Poonam A. Arora
            Puma Biotechnology: Risk Reward Imbalance $PBYI http://seekingalpha.com/a/1ciql
            Jun 12, 1:28 PM
            Reply (3)
          • View all 3 replies
            • Poonam A. Arora: Yes $61.88/share is the bull case, takes the most optimistic view. The base case is obviously much lower.
              Jun 13, 4:58 AM
            • matratra: On positive note, 74% shares are own by big mutual funds.
              Jun 13, 8:19 AM
              • Poonam A. Arora
                Puma Biotechnology: ISPY2 Data Added Little To The Neratinib Conversation $PBYI http://seekingalpha.com/a/19uv7
                Apr 15, 5:52 AM
                Reply
                  • Poonam A. Arora
                    Puma Biotechnologies: A Short Thesis For Investors $PBYI http://seekingalpha.com/a/18n3n
                    Mar 13, 5:00 AM
                    Reply
                      • Poonam A. Arora
                        $MDVN Based on my analysis Xtandi revenues this year will beat analyst consensus of $213 million.
                        3/30/13
                        Reply